The 31st One Mind Music Festival on September 13, 2025 will be hosted at Staglin Family Vineyard in Rutherford, CA. The ...

Bristol-Myers Squibb Company (NYSE:BMY) is one of the top stocks sold by hedge funds. On July 28, Bristol Myers, in ...

The FDA has granted Breakthrough Therapy Designation to Bristol Myers Squibb (BMY) and SystImmune’s experimental drug iza-bren for treating advanced EGFR-mutant lung cancer after prior therapies fail, ...

US pharma major Bristol Myers Squibb has appointed Dr Nathan Pennell as senior vice president, worldwide head of medical ...

Bristol-Myers Squibb Company (($BMY)) announced an update on their ongoing clinical study. Study Overview: Bristol-Myers ...

Systlmmune and BMS’ ACD treats patients with previously treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer.

With Bristol Myers Squibb’s long-standing expertise in developing and commercializing medicines on a global scale and legacy in neuroscience, KarXT and the other assets in our pipeline will be ...

Bristol Myers Squibb Buys Out Cancer Cell Therapy Partner 2seventy Bio in $286M Deal Multiple myeloma cell therapy Abecma is the lone remaining asset of 2seventy Bio, which spun out from Bluebird ...

Bristol-Myers Squibb offers strong cash flow, solid growth, and a high yield despite pricing pressure and pipeline risks. Read why BMY stock is a buy.

By Michael Erman (Reuters) -Bristol Myers Squibb posted much better-than-expected second-quarter results on Wednesday on strong sales of its most established and best-selling brands, blood thinner ...

Bristol Myers Squibb BMY -1.9% (NYSE: BMY) reported its Q3 results last month, with revenues meeting and earnings beating the street estimates, and we believe that BMY stock is undervalued, as ...

Bristol-Myers Squibb’s P/E Multiple of 11.8x on average consensus EPS of 4.28 for 2019, is lower than 13.0x for Pfizer, 17.3x for Merck, and 15.3x for J&J.